medigraphic.com
ISSN 1870-2821 (Print)
Organo Oficial de la Asociación Mexicana de Mastología

2019, Number 2-3

<< Back Next >>

Rev Mex Mastol 2019; 9 (2-3)

Breast cancer triple negative and its relation with obesity

González-García-Rojas EA, Murillo-Ortiz B, Murguía-Pérez M, Suárez-García D, Martínez-Garza S

Language: Spanish
References: 27
Page: 38-43
PDF size: 248.88 Kb.


ABSTRACT

Introduction: It is proposed that the relationship between obesity and the risk of developing hormonal breast cancer in postmenopausal women is due to the mechanism of hormonal conversion of peripheral fats to estrogen by the aromatase enzyme. In contrast, as triple-negative cancers do not have hormone dependence, their relationship with overweight is under discussion. Objective: To know the presence of obesity in women diagnosed with breast cancer with triple negative status. Material and methods: A retrospective, observational longitudinal study was carried out, which included 70 female patients diagnosed with mammary carcinoma, who attended Unidad Médica de Alta Especialidad No. 1 Bajío of the Instituto Mexicano del Seguro Social in the period between January 2017 and June 2018. triple negative state, histological type and tumor grade was extracted from the pathology report and the clinical data were obtained from the Oncology Service database. Results: In our study, the average age was 52.32 ± 10.94 years, the most frequent age group was between 60-73 years. The predominant tumor size was between 2-5 cm in 48% of the patients. The media BMI was 29.08 ± 3.85, 40% were overweight and 39.9% obesity. 33.3% obesity grade I, 6.6% obesity grade II and 20% with normal weight. 44% were diagnosed in stage II B, 50% in stage III A. The most frequent histopathological strain was infiltrating ductal carcinoma in 58% of the cases and 54% with intermediate degree of malignancy. Conclusions: The present study showed that 80% of the patients with a diagnosis of mammary carcinoma with triple negative receptor status are overweight and obese.


REFERENCES

  1. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast. 2010; 19: 312-321.

  2. Zaharia M, Gómez H. Cáncer de mama triple negativo: una enfermedad de difícil diagnóstico y tratamiento. Rev Peru Med Exp Salud Publica. 2013; 30 (4): 649-656.

  3. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121 (7): 2750-2767.

  4. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011; 117 (16): 3658-3669.

  5. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J. 2008; 14 (5): 456-463.

  6. Dean SJ, Rhodes A. Triple negative breast cancer: the role of metabolic pathways. Malays J Pathol. 2014; 36 (3): 155-162.

  7. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013; 137 (1): 307-314.

  8. Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control. 2011; 22 (3): 399-405.

  9. Wang ZQ, Milne K, Derocher H, Webb JR, Nelson BH, Watson PH. PD-L1 and intratumoral immune response in breast cancer. Oncotarget. 2017; 8: 51641-51651.

  10. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013; 18 (2): 123-133.

  11. McDonnell DP, Park S, Goulet MT, Jasper J, Wardell SE, Chang CY et al. Obesity, cholesterol metabolism and breast cancer pathogenesis. Cancer Res. 2014; 74 (18): 4976-4982.

  12. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007; 25 (30): 4772-4778.

  13. Vrieling A, Buck K, Kaaks R, Chang-Claude J. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat. 2010; 123 (3): 641-649.

  14. Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008; 114 (1): 71-83.

  15. Chan DS, Norat T. Obesity and breast cancer: not only a risk factor of the disease. Curr Treat Options Oncol. 2015; 16 (5): 22.

  16. Simpson ER, Brown KA. Minireview: obesity and breast cancer: a tale of inflammation and dysregulated metabolism. Mol Endocrinol. 2013; 27 (5): 715-725.

  17. Maiti B, Kundranda MN, Spiro TP, Daw HA. The association of metabolic syndrome with triplenegative breast cancer. Breast Cancer Res Treat. 2010; 121 (2): 479-483.

  18. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998; 351 (9113): 1393-1396.

  19. Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, Arslan AA, Shore RE, Koenig KL et al. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. Cancer Epidemiol Biomarkers Prev. 2005; 14 (1): 48-52.

  20. Yu H, Jin F, Shu XO, Li BD, Dai Q, Cheng JR et al. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev. 2002; 11 (8): 705-712.

  21. Allen NE, Roddam AW, Allen DS, Fentiman IS, Dos Santos-Silva I, Peto J et al. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer. 2005; 92 (7): 1283-1287.

  22. Davis SL, Eckhardt SG, Tentler JJ, Diamond JR. Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol. 2014; 6 (3): 88-100.

  23. Kruk J. Overweight, obesity, oxidative stress and the risk of breast cancer. Asian Pac J Cancer Prev. 2014; 15 (22): 9579-9586.

  24. Tan GH, Taib NA, Choo WY, Teo SH, Yip CH. Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country. Asian Pac J Cancer Prev. 2009; 10 (3): 395-398.

  25. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009; 115 (2): 423-428.

  26. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011; 29 (19): 2628-2634.

  27. Fornier M, Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J. 2012; 18 (1): 41-51.




2020     |     www.medigraphic.com